| | Business Summary | | BioCryst
Pharmaceuticals,
Inc.
is
a
biotechnology
company
focused
on
the
development
of
pharmaceuticals
for
the
treatment
of
infectious,
inflammatory
and
cardiovascular
diseases
and
disorders.
The
Company's
most
advanced
drug
candidate,
RWJ-270201
(formerly
referred
to
as
BCX-1812),
is
an
influenza
neuraminidase
inhibitor
designed
to
treat
and
prevent
viral
influenza.
The
Company
has
licensed
this
drug
candidate
to
The
R.W.
Johnson
Pharmaceutical
Research
Institute
and
Ortho-McNeil
Pharmaceutical,
Inc.,
both
Johnson
&
Johnson
companies.
The
Company
focuses
its
drug
development
efforts
on
the
development
of
potent,
selective
inhibitors
of
enzymes
associated
with
several
diseases. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | BioCryst
Pharmaceuticals
is
a
biotechnology
company
focused
on
the
development
of
pharmaceuticals
for
the
treatment
of
infectious,
inflammatory
and
cardiovascular
diseases
and
disorders.
For
the
six
months
ended
6/30/01,
revenues
rose
64%
to
$6.4
million.
Net
loss
before
accounting
change
fell
84%
to
$425
thousand.
Revenues
reflect
an
increase
as
a
result
of
the
implementation
of
SAB
101.
Lower
loss
reflects
decreased
legal
fees
and
stockholder
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Charles Bugg, Ph.D., 59
Chairman,
CEO | $424K | $1.1M | J. Claude Bennett, M.D., 67
Pres,
COO, Director | 273K | 273K | W. Randall Pittman, 47
CFO,
Assistant Sec., Treasurer | 198K | -- | John Montgomery, Ph.D., 76
CSO,
Sr. VP, Sec. | 115K | 975K | John Urhin, 48
VP,
Corp. Devel. | 239K | -- | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/b/bcrx.gif)